Abstract
Background
We sought to determine the prevalence of diabetes mellitus (DM) newly diagnosed by
elevated glycated hemoglobin (HbA1c) in patients undergoing percutaneous coronary
intervention (PCI) and its association with 1-year clinical outcomes.
Methods
We prospectively enrolled consecutive patients undergoing PCI (2011–2013). HbA1c levels
were assessed during the index hospitalization and newly diagnosed DM was defined
as HbA1c ≥ 6.5% in the absence of the previous diagnosis. The primary outcome was MACCE (Major
Adverse Cerebro- and Cardiovascular Events) defined as death, stroke, PCI or acute
myocardial infarction at 1 year.
Results
Diabetes was previously diagnosed in 391 (34%) patients (DM group), 221 (19%) had
newly diagnosed DM based on the HbA1c level and 539 (47%) did not have diabetes (Non-DM).
In DM group HbA1c was 7.80 ± 1.36% as compared with 7.62 ± 1.30% in patients with newly diagnosed DM (p < 0.001). These patients were younger (62.0 ± 11.3 years) compared to DM (67.9 ± 10.4 years) and non-DM (63.7 ± 13.0) patients, p < 0.001. 1-year MACCE rates were 14.8%, 19.5% and 27.96% in the non-DM, newly diagnosed
DM and DM groups, respectively (p < 0.001). Multivariate analysis showed that compared to non-DM, the adjusted one-year
hazard ratios for MACCE were 1.75 and 1.40 in patients with known DM and newly diagnosed
DM, respectively (p < 0.05 for both).
Conclusion
Newly diagnosed DM based on peri-procedural HbA1c is common and associated with increased
short and long term risk for adverse outcomes. Our results may warrant routine screening
for DM in all patients undergoing PCI.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry.Am J Cardiol. 2011; 107: 1155-1162
- Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med. 2014; 371 ([dec 4]): 23
- Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction the valsartan in acute myocardial infarction (VALIANT) Trial.Circulation. 2004; 110: 1572-1578
- Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry.Circulation. 1996; 94: 1818-1825
- Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A Serial Intravascular Ultrasound Study.Circulation. 1997; 95: 1366-1369
- Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA. 2005; 293: 2126-2130
- Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.J Am Coll Cardiol. 2008; 51: 708-715
- Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.N Engl J Med. 2007; 356: 1030-1039
- Differences in clinical and angiographic outcomes with different drug-eluting stents in Japanese patients with and without diabetes mellitus.J Cardiol. 2012; 60: 361-366
- Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention.Am Heart J. 2003; 146: 351-358
- Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus.Am Heart J. 2003; 145: 1013-1021
- Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention.J Am Coll Cardiol. 2004; 43: 8-14
- Analytical evaluation of hemoglobin A1c dual kit assay on Bio-Rad Variant II: an automated HPLC hemoglobin analyzer for the management of diabetic patients.Clin Biochem. 2003; 36: 317-320
- ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J. 2012; 33: 2569-2619
- AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes.J Am Coll Cardiol. 2014; 64: 2645-2687
- Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.J Am Soc Echocardiogr. Dec 2005; 18: 1440-1463
- Undiagnosed diabetic patients undergoing elective percutaneous coronary interventions have a high rate of mortality.Circulation. 2009; 120: S548
- Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome.Am J Cardiol. 2005; 96: 363-365
- Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology.Eur Heart J. May 14 2015; 36: 1171-1177
- Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome.Am Heart J. 2013; 165: 918-925
- Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.N Engl J Med. 2010; 362: 800-811
- Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment–elevation myocardial infarction treated with percutaneous coronary intervention.Circulation. 2011; 124: 704-711
- Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting.Cardiovasc Diabetol. Jul 17 2012; 11: 82
- Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation.Am J Cardiol. 2009; 104: 41-45
- Glycosylated hemoglobin and outcomes in diabetic patients with acute myocardial infarction after successful revascularization with stent placement: findings from the Guthrie Health Off-Label Stent (GHOST) investigators.J Interv Cardiol. 2012; 25: 262-269
- Influence on prognosis and prevalence of stress hyperglycemia in a cohort of patients with acute coronary syndrome.Rev Bras Ter Intensiva. 2012 Dec; 24: 352-356
- Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes.Circulation. Jun 14 2005; 111: 3078-3086
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).Eur Heart J. 2007; 28: 88-136
- ESC Committee for Practice Guidelines (CPG): management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.Eur Heart J. 2008; 29: 2909-2945
- Hyperglycaemia in acute coronary syndromes: summary of NICE guidance.BMJ. 2011; 343: d6646
- Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.Circulation. 2008; 117: 1610-1619
- Acute Coronary Syndrome Israeli Survey (ACSIS), survey findings and temporal trends 2000–2013.April – May 2013
- The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.Ann Intern Med. 2005; 142: 611-619
Zinman B, Wanner C, Lachin J.M, et al., (the EMPA-REG OUTCOME Investigators). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM, 373(22), 2117–2128.
- Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.Ann Intern Med. 2004; 141: 929-937
Article info
Publication history
Published online: September 21, 2016
Accepted:
September 9,
2016
Received:
August 23,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
